RxDoctor Payments Data

Michael Schmidt, MD

Family Medicine · Deerfield Beach, FLNPI 1063583086

Payments from drug & device makers

$3,440in general payments, 2019–2025

Across 80 payments — averaging $43.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novartis$309
  • Amgen$137
  • Amarin Pharma, Inc.$121
  • Boehringer Ingelheim$83
  • GSK$71
  • plus $326 from 11 others

What the payments were for

  • Food & beverage$3,42399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,440 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$258,078
Medicare patients
278
Services billed
2,055

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$74,592
OzempicSemaglutide62$67,606
JardianceEmpagliflozin27$42,210
XareltoRivaroxaban32$36,825
SymbicortBudesonide/Formoterol Fumarate19$9,159
Incruse ElliptaUmeclidinium Bromide11$3,969
Atorvastatin Calcium358$3,459
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$3,337
Omeprazole221$3,293
DilantinPhenytoin Sodium Extended11$2,656
Levothyroxine Sodium194$2,019
Simvastatin178$1,602
Metformin Hcl249$1,366
Rosuvastatin Calcium108$1,323
Lisinopril220$1,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$53$67,60662 claims
Boehringer IngelheimJardiance$83$42,21027 claims
Johnson & JohnsonXarelto$2,394$36,82532 claims
AstraZenecaSymbicort$47$9,15919 claims
GSKIncruse Ellipta$71$3,96911 claims
AbbVieSynthroid$18$49511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Deerfield Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →